Clinical trials: Normal Healthy
Healthy
Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers
The purpose of this study is 1) to test the safety of S-equol in healthy volunteers and 2) to see how quickly S-equol enters the bloodstream, is distributed in the body, and broken down and removed, when taken with food or…
- Trial name
- NCT00787007
- Testing
- S-equol
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ausio Pharmaceuticals, LLC
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Healthy
Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets
The objective of this open-label, randomized, two-period crossover study was to compare the oral bioavailability of a Mallinckrodt test tablet formulation of oxycodone 30 mg to an equivalent oral dose of a commercially available…
- Trial name
- NCT00853736
- Testing
- Roxicodone™ tablet 30 mg, Oxycodone hydrochloride tablet 30 mg
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Healthy
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units.
- Trial name
- INFUSE-NSLR (NCT00656370)
- Testing
- recombinant human hyaluronidase
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Healthy
A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form
In this study, a 10 mg dose of CP-690,550 will be given to study subjects on two separate occasions by two different routes of administration: One time by mouth in tablet form and one time by vein (intravenous form).
- Trial name
- NCT01143805
- Testing
- Tasocitinib 10 mg oral tablet, Tasocitinib 10 mg IV Infusion
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pharmacokinetics
Phase I Study PK Study With OXP005 and Naprosyn
The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions.
- Trial name
- NCT02351024
- Testing
- OXP005, Naprosyn®
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Oxford Pharmascience Ltd
Healthy
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions
To compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in fasted subjects.
- Trial name
- NCT00863941
- Testing
- Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Hepatic Impairment
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.
- Trial name
- NCT00432627
- Testing
- Deferasirox
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Major Depressive Disorder
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers
- Trial name
- NCT04981561
- Testing
- zelquistinel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Syndeio Biosciences, Inc
Normal Healthy
Topical Multiple Ascending Dose Study for PF-06423264
The current study is the first clinical trial proposed with PF-06423264. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of multiple ascending doses of PF-06423264 to…
- Trial name
- NCT02778477
- Testing
- PF-06423264
- Where
- Belgium
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Impairment
Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function
This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.
- Trial name
- NCT02452801
- Testing
- ALKS 5461
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Tuberculosis
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
This is a phase 1, "first in man" study to evaluate single oral doses (5-300 mg) of SQ109, a new investigational drug being developed for treatment of tuberculosis.
- Trial name
- NCT01585636
- Testing
- SQ109
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Psoriasis
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).
- Trial name
- ADENOIMMUNE (NCT03798236)
- Testing
- PBF-1650 oral capsules
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Palobiofarma SL
Rheumatic Diseases
Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
- Trial name
- NCT02291471
- Testing
- T0001，10mg, T0001，20mg, T0001，35mg
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers
The main purpose of this study is to assess the safety and pharmacokinetics of SRT2379 (25, 75, 250, 500, 1000, 2000, and 3000 mg/day [fasted] and 500 mg/day [fed]) in healthy male volunteers.
- Trial name
- NCT01018628
- Testing
- SRT2379
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatic Insufficiency
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
- Trial name
- NCT06858696
- Testing
- Mavorixafor
- Where
- 4 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- X4 Pharmaceuticals
Glaucoma Patients, Retina Patients
Performance Evaluation of Dream OCT: AP Study
This study will evaluate the clinical performance of a new swept-source OCT imaging device, the VG200D, and to evaluate substantial equivalence with a predicate device, the Cirrus 5000.
- Conditions
- Glaucoma Patients, Retina Patients, Eyes With Corneal Abnormality, Normal Healthy Eyes
- Trial name
- NCT07355491
- Testing
- This is an observational study only, all patients are imaged on the investigational device
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Intalight, Inc
Breast Cancer
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 24-30 subjects. Subjects will take the SHR6390 on Day1.
- Trial name
- NCT05515289
- Testing
- SHR6390
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.